Andexxa is a recombinant modified human factor Xa protein that received accelerated approval in 2018 for reversal of anticoagulation with rivaroxaban or apixaban due to life-threatening or ...
Fesilty is supplied as a lyophilized powder for reconstitution in a single-dose vial containing approximately 1g of human fibrinogen.
MPR, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient outcomes.